PMID- 28446541
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20190221
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 70
IP  - 12
DP  - 2017 Dec
TI  - Nuclear survivin expression correlates with endoglin-assessed 
      microvascularisation in laryngeal carcinoma.
PG  - 1033-1037
LID - 10.1136/jclinpath-2016-204230 [doi]
AB  - AIMS: Survivin-a member of the family of inhibitor of apoptosis proteins that 
      control cell division, apoptosis and metastasis-is overexpressed in virtually all 
      human cancers, including laryngeal squamous cell carcinoma (LSCC). Recent 
      findings also correlate survivin expression with the regulation of angiogenesis. 
      The novel main aim of this study was a preliminary investigation into the 
      potential role of survivin expression in LSCC neoangiogenesis, as determined by 
      endoglin-assessed microvascular density (MVD). METHODS: Immunohistochemical 
      expression of nuclear survivin and endoglin-assessed MVD were ascertained by 
      image analysis in 75 consecutive LSCCs. RESULTS: Statistical analysis disclosed a 
      strong direct correlation between nuclear survivin expression and MVD. Patients 
      whose nuclear survivin expression was >/=6.0% had a significantly higher LSCC 
      recurrence rate, and a significantly shorter disease-free survival (DFS) than 
      those with a nuclear survivin expression <6.0%. The LSCC recurrence rate was also 
      higher and the DFS shorter in patients with endoglin-assessed MVD >/=6.89%. The OR 
      for recurrence was 2.79 in patients with LSCC with a nuclear survivin expression 
      >/=6.0%, and 12.31 in those with an MVD>/=6.89%. CONCLUSIONS: Survivin-targeting 
      strategies to enhance tumour cell response to apoptosis and inhibit tumour growth 
      should receive more attention with a view to developing agents for use in 
      multimodality advanced LSCC treatment, or combined with conventional 
      chemotherapy. Given the present preliminary evidence in LSCC, survivin targeting 
      should also be further investigated for anti-angiogenic purposes, to reduce 
      tumour blood flow and induce cancer necrosis.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Marioni, Gino
AU  - Marioni G
AD  - Department of Neurosciences DNS, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Ottaviano, Giancarlo
AU  - Ottaviano G
AD  - Department of Neurosciences DNS, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Marchese-Ragona, Rosario
AU  - Marchese-Ragona R
AD  - Department of Neurosciences DNS, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Fasanaro, Elena
AU  - Fasanaro E
AD  - Department of Radiotherapy, Veneto Institute of Oncology, IOV-IRCCS, Padova, 
      Italy.
FAU - Tealdo, Giulia
AU  - Tealdo G
AD  - Department of Neurosciences DNS, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Zanotti, Claudia
AU  - Zanotti C
AD  - Department of Neurosciences DNS, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Randon, Benedetto
AU  - Randon B
AD  - Department of Neurosciences DNS, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Giacomelli, Luciano
AU  - Giacomelli L
AD  - Department of Medicine DIMED, University of Padova, Italy.
FAU - Stellini, Edoardo
AU  - Stellini E
AD  - Department of Neurosciences DNS, Odontostomatology Institute, University of 
      Padova, Padova, Italy.
FAU - Blandamura, Stella
AU  - Blandamura S
AD  - Department of Medicine DIMED, University of Padova, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170426
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ENG protein, human)
RN  - 0 (Endoglin)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Survivin)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Squamous Cell/*chemistry/mortality/pathology/surgery
MH  - Cell Nucleus/*chemistry/pathology
MH  - Disease-Free Survival
MH  - Endoglin/*analysis
MH  - Female
MH  - Head and Neck Neoplasms/*chemistry/mortality/pathology/surgery
MH  - Humans
MH  - Immunohistochemistry
MH  - Inhibitor of Apoptosis Proteins/*analysis
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*chemistry/mortality/pathology/surgery
MH  - Male
MH  - Microvessels/*chemistry/pathology
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Odds Ratio
MH  - Risk Factors
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Survivin
MH  - Time Factors
OTO - NOTNLM
OT  - ANGIOGENESIS
OT  - CARCINOMA
OT  - LARYNX
COIS- Competing interests: None declared.
EDAT- 2017/04/28 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/04/28 06:00
PHST- 2016/11/14 00:00 [received]
PHST- 2017/03/02 00:00 [revised]
PHST- 2017/04/08 00:00 [accepted]
PHST- 2017/04/28 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/04/28 06:00 [entrez]
AID - jclinpath-2016-204230 [pii]
AID - 10.1136/jclinpath-2016-204230 [doi]
PST - ppublish
SO  - J Clin Pathol. 2017 Dec;70(12):1033-1037. doi: 10.1136/jclinpath-2016-204230. 
      Epub 2017 Apr 26.